Clinical trial expands evidence base for the Wobenzym® brand
Clinical trial expands evidence base for the Wobenzym® brand
New scientific publication reports that an oral enzyme combination was able to reduce markers of inflammation and to alleviate pain in patients after undergoing elective total hip replacement
A recent clinic trial is expanding the evidence base for the Wobenzym® brand. The results are published in Therapeutic Advances in Musculoskeletal Disease. The trial evaluated the effects of peri-operative use of an oral enzyme combination (OEC) with bromelain, trypsin and the flavonoid rutoside in patients undergoing elective total hip replacement (THRs).
The trial found that compared with the placebo group, the OEC group had significantly lower blood C-reactive protein levels (a marker of inflammatory activity in the blood) during the acute post-operative phase, the first seven days after THR. Patients in the OEC group also reported significantly less post-operative pain than those in the control group during this early phase of recovery from surgery. OEC was well tolerated and showed an overall safety profile similar to the placebo.
THRs are one of the most common types of surgery in the western world and are performed increasingly frequently due to consequences of osteoarthritis. Patients are strongly encouraged to become mobile as soon as possible after surgery but they are often limited by post-operative pain. This is complicated by fact that the broad use of multimodal analgesics such as NSAIDs is somewhat restricted due to potential undesirable side effects shortly after surgery.
The clinical study comprised 33 patients eligible for primary elective cementless THR due to osteoarthritis. They were recruited from a tertiary orthopaedic hospital in the Czech Republic. Eligible individuals were randomised to either OEC or placebo and followed for 42 days after surgery.
This is the first randomized and placebo-controlled clinical study exploring OEC effects in people with long-term complications of hip osteoarthritis scheduled for THR. Results indicate that OEC has the potential to significantly reduce blood (systemic) inflammation and to alleviate patient self-reported pain already within the first week after surgery. This suggests that OEC could be an attractive treatment option to improve post-operative THR recovery and to facilitate early mobilization after surgery.
About Wobenzym
Wobenzym® is an oral enzyme combination with Bromelain, Trypsin and includes the flavonoid Rutoside. It is approved as a pharmaceutical drug in Germany and many other countries in the EU and CIS/CEE region, also under the name Phlogenzym®, and supported by clinical evidence. A 2016 published meta-analysis has confirmed that Wobenzym® is as effective as gold standard NSAID Diclofenac in reducing joint pain, increasing joint function and mobility and yet has a favorable safety profile bringing a clear clinical benefit to patients with knee osteoarthritis. While it is well established that Wobenzym® is safe and has proven efficacy in painful conditions, inflammation and OA, this clinical study is providing further insights in post-operative rehabilitation.
Wobenzym® has an extensive history in Systemic Enzyme Therapy spanning over 50 years. The Wobenzym® product range is offered in Europe as well as North America and is globally recognized in the joint health market. Wobenzym products, in addition to their rich clinical history, are well-known within the medical community for numerous benefits in the health of joints, muscles, and tendons. The line has been expanded by the Wobecare® brand including products like a CBD cream. Wobenzym® prides itself on bringing high quality products to patients and practitioners worldwide. Wobenzym® has the mission of leading the way to provide solutions that maximize the body´s ability to protect and restore itself. WOBENZYM® - | Nestlé Health Science (nestlehealthscience.com)
About Nestlé Health Science (NHSc)
Nestlé Health Science, a leader in the science of nutrition, is a globally managed business unit of Nestlé. We are committed to redefining the management of health, offering an extensive portfolio of science-based consumer health, medical nutrition, pharmaceutical therapies, and vitamin and supplement brands. Our extensive research network provides the foundation for products that empower healthier lives through nutrition. Headquartered in Switzerland, we have more than 12,000 employees around the world, with products available in more than 140 countries. www.nestlehealthscience.com
Media contact:
Jacquelyn.Campo@nestle.com +41 79 598 1163
